Want to see KYNB full AI Analyst Report?
KYNB Stock Chart & Stats
$7.32
>-$0.01(-1.28%)
At close: 4:00 PM EST
$7.32
>-$0.01(-1.28%)
Day’s Range― - ―
52-Week Range$6.32 - $12.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)28.30K
Market Cap
$28.54M
Enterprise Value-$6.04
Total Cash (Recent Filing)$87.24M
Total Debt (Recent Filing)$19.25M
Price to Earnings (P/E)0.2
Beta0.84
Next Earnings
Aug 10, 2026EPS Estimate
-3.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)41.56
Shares Outstanding4,048,112
10 Day Avg. Volume7,208
30 Day Avg. Volume28,298
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$36.00Price Target Upside391.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-13.75
Revenue Forecast (FY)$9.95M
Bulls Say, Bears Say
Bulls Say
Cash Runway Into 2028A $100.3M liquidity position with management guidance to fund operations into 2028 materially lowers near-term financing risk and gives the company time to reach key clinical inflection points. That runway supports executing trials and regulatory interactions without immediate capital raises.
Zero Debt Capital StructureHaving no debt eliminates interest expense and reduces default risk, providing flexibility to allocate capital to R&D and trial enrollment. This durable structural advantage makes funding choices cleaner and lowers the fixed-cost burden while clinical programs progress.
Clear Clinical Milestones And Biomarker StrategyDefined timelines for a Phase II interim readout and a planned Phase III start provide a visible development roadmap. Combined with FG-3180 PET biomarker work and constructive FDA feedback for roxadustat, this structured strategy can materially de-risk program design and improve prospects for a targeted Phase III.
Bears Say
Persistent Negative Operating Cash FlowConsistent negative operating and free cash flow indicates the business continues to burn cash to fund operations and development. Even with current reserves, continued negative OCF elevates refinancing risk, constrains optionality for parallel programs, and increases dependency on external funding.
Negative Shareholders' Equity In TTMNegative equity signals accumulated losses and reduces the balance-sheet cushion available to absorb further operating deficits. This structural weakness can hinder access to secured financing, complicate partnership negotiations, and raise long-term solvency concerns if losses persist.
Pipeline Dependent On Binary Clinical ReadoutsA significant portion of the company's future value hinges on upcoming trial outcomes and enrollment execution. Reliance on binary clinical readouts concentrates downside risk: missed endpoints, slow enrollment, or regulatory setbacks could materially reduce prospects and force strategic pivots or financing under duress.
Kyntra Bio News
KYNB FAQ
What was Kyntra Bio, Inc.’s price range in the past 12 months?
Kyntra Bio, Inc. lowest stock price was $6.32 and its highest was $12.60 in the past 12 months.
What is Kyntra Bio, Inc.’s market cap?
Kyntra Bio, Inc.’s market cap is $28.54M.
When is Kyntra Bio, Inc.’s upcoming earnings report date?
Kyntra Bio, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 12 days.
How were Kyntra Bio, Inc.’s earnings last quarter?
Kyntra Bio, Inc. released its earnings results on May 11, 2026. The company reported -$3.76 earnings per share for the quarter, missing the consensus estimate of -$3.355 by -$0.405.
Is Kyntra Bio, Inc. overvalued?
According to Wall Street analysts Kyntra Bio, Inc.’s price is currently Undervalued.
Does Kyntra Bio, Inc. pay dividends?
Kyntra Bio, Inc. does not currently pay dividends.
What is Kyntra Bio, Inc.’s EPS estimate?
Kyntra Bio, Inc.’s EPS estimate is -3.18.
How many shares outstanding does Kyntra Bio, Inc. have?
Kyntra Bio, Inc. has 4,048,112 shares outstanding.
What happened to Kyntra Bio, Inc.’s price movement after its last earnings report?
Kyntra Bio, Inc. reported an EPS of -$3.76 in its last earnings report, missing expectations of -$3.355. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Kyntra Bio, Inc.?
Currently, no hedge funds are holding shares in KYNB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyntra Bio, Inc.
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
KYNB Company Deck
KYNB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress across two key programs (FG-3246/FG-3180 and roxadustat), supportive subgroup efficacy data, validated mitigation of a key ADC safety issue, improved financial discipline with reduced R&D and SG&A, revenue growth, and a cash runway into 2028. Key risks include ongoing net losses, small revenue base, an unresolved biomarker statistical significance that 'just missed' in the IST, residual safety concerns around neutropenia, and reliance on upcoming binary clinical readouts and enrollment execution. On balance, the positives (clinical signals, validated mitigation strategy, constructive FDA feedback on roxadustat, cash runway and expense reductions) outweigh the lowlights, though the company remains dependent on near-term trial execution.View all KYNB earnings summariesKYNB Stock 12 Month Forecast
Average Price Target
$36.00
▲(391.80% Upside)
Technical Analysis
Ownership Overview
3.37% Insiders
22.61% Mutual Funds
10.71% Other Institutional Investors
59.44% Public Companies and
Individual Investors